### Case 23-11661-KBO Doc 488 Filed 05/13/24 Page 1 of 12

UNI	UNITED STATES BANKRUPTCY COURT				
	DISTRICT OF Delaware				
In Re. Lodo Therapeutics Corporation	0	Case No. <u>23-11662</u>			
	§	Lead Case No. <u>23-11661</u>			
Debtor(s)	ş	⊠ Jointly Administered			
<b>Monthly Operating Report</b>		Chapter 11			
Reporting Period Ended: 02/23/2024		Petition Date: <u>10/03/2023</u>			
Months Pending: 5		Industry Classification: 5 4 1 7			
Reporting Method:	Accrual Basis (•	Cash Basis 🔿			
Debtor's Full-Time Employees (current):		0			
Debtor's Full-Time Employees (as of date	of order for relief):	0			
<b>Supporting Documentation</b> (check all (For jointly administered debtors, any required		non-consolidated basis for each debtor)			
Statement of cash receipts and disl	bursements				

Balance sheet containing the summary and detail of t	the assets, liabilities and equity (net worth) or deficit
--	---

- Statement of operations (profit or loss statement)
- Accounts receivable aging
- Postpetition liabilities aging
- Statement of capital assets
- Schedule of payments to professionals
- Schedule of payments to insiders
- All bank statements and bank reconciliations for the reporting period
- Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Sophie Rogers Churchill

Signature of Responsible Party

05/13/2024

Date

Sophie Rogers Churchill

Printed Name of Responsible Party

1201 N. Market St. Wilmington, DE 19801 Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

UST Form 11-MOR (12/01/2021)

#### Doc 488 Filed 05/13/24 Page 2 of 12 Case 23-11661-KBO

#### Debtor's Name Lodo Therapeutics Corporation

Case No. 23-11662

Pa	rt 1: Cash Receipts and Disbursements	<b>Current Month</b>	Cumulative
a.	Cash balance beginning of month	\$1,510,187	
b.	Total receipts (net of transfers between accounts)	\$0	\$0
c.	Total disbursements (net of transfers between accounts)	\$0	\$1,510,187
d.	Cash balance end of month (a+b-c)	\$1,510,187	
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$0	\$1,510,187
	rt 2: Asset and Liability Status of generally applicable to Individual Debtors. See Instructions.)	Current Month	
a.	Accounts receivable (total net of allowance)	\$0	
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$0	
c.	Inventory (Book $\bigcirc$ Market $\bigcirc$ Other $\bigcirc$ (attach explanation))	\$0	
d	Total current assets	\$0	
e.	Total assets	\$510,187	
f.	Postpetition payables (excluding taxes)	\$0	
g.	Postpetition payables past due (excluding taxes)	\$0	
h.	Postpetition taxes payable	\$0	
i.	Postpetition taxes past due	\$0	
j.	Total postpetition debt (f+h)	\$0	
k.	Prepetition secured debt	\$0	
1.	Prepetition priority debt	\$0	
m.	Prepetition unsecured debt	\$2,068,814	
n.	Total liabilities (debt) (j+k+l+m)	\$2,068,814	
0.	Ending equity/net worth (e-n)	\$-1,558,627	
Pa	rt 3: Assets Sold or Transferred	Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$0
b.	Total payments to third parties incident to assets being sold/transferred		<u>*0</u>
c.	outside the ordinary course of business Net cash proceeds from assets sold/transferred outside the ordinary	\$0	\$0
ι.	course of business (a-b)	\$0	\$0

	rt 4: Income Statement (Statement of Operations) of generally applicable to Individual Debtors. See Instructions.)	Current Month	Cumulative
a.	Gross income/sales (net of returns and allowances)	\$0	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$0	
c.	Gross profit (a-b)	\$0	
d.	Selling expenses	\$0	
e.	General and administrative expenses	\$0	
f.	Other expenses	\$4,240,040	
g.	Depreciation and/or amortization (not included in 4b)	\$0	
h.	Interest	\$0	
i.	Taxes (local, state, and federal)	\$0	
j.	Reorganization items	\$0	
k.	Profit (loss)	\$-4,240,040	\$-4,240,040

## Case 23-11661-KBO Doc 488 Filed 05/13/24 Page 3 of 12

#### Debtor's Name Lodo Therapeutics Corporation

5: Pr	ofessional Fees and Expenses					
			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
Det	otor's professional fees & expenses (bank	ruptcy) Aggregate Total				
Iten	nized Breakdown by Firm					
	Firm Name	Role				
i						
ii						
iii						
iv						
v						
vi						
vii						
viii	i					
ix						
х						
xi						
xii						
xiii	i					
xiv	,					
xv						
xvi	i l					
xvi	ii					
xvi	iii					
xix						
xx						
xxi	i					
xxi	ii					
xxi	iii					
xxi	iv l					
XXV	V					
xxv	vi					
xxv	vii					
xxv	viii					
xxi	x					
XXX	x					
XXX						
xxx						
xxx						
xxx						
xxx						
xxx						

xxxvii			
xxxvii			
xxxix			
xl			
xli			
xlii			
xliii			
xliv			
xlv			
xlvi			
xlvii			
xlviii			
xlix			
1			
li			
lii			
liii			
liv			
lv			
lvi			
lvii			
lviii			
lix			
lx			
lxi			
lxii			
lxiii			
lxiv			
lxv			
lxvi			
lxvii			
lxviii			
lxix			
lxx			
lxxi			
lxxii			
lxxiii			
lxxiv			
lxxv			
lxxvi			
lxxvii			

		-		•	•
	lxxix				
	lxxx				
	lxxxi				
	lxxxii				
	lxxxii				
	lxxxiv				
	lxxxv				
	lxxxvi				
	lxxxvi				
	lxxxvi				
	lxxxix				
	хс				
	xci				
	хсіі				
	xciii				
	xciv				
	xcv				
	xcvi				
	xcvii				
	xcviii				
	xcix				
	c				
	ci				
		Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
).	Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total				
	Itemized Breakdown by Firm				

			Approved Current Month	Approved Cumulative	Month	Cumulative
Debt	Debtor's professional fees & expenses (nonbankruptcy) Aggregate Total					
Item	ized Breakdown by Firm					
	Firm Name	Role				
i						
ii						
iii						
iv						
v						
vi						
vii						
viii						
ix						
х						
xi						
xii						
xiii						
xiv						

XV			
xvi			
xvii			
xviii			
xix			
xx			
xxi			
xxii			
xxiii			
xxiv			
xxv			
xxvi			
xxvii			
xxviii			
xxix			
xxx			
xxxi			
xxxii			
xxxiii			
xxxiv			
XXXV			
xxxvi			
xxxvii			
xxxvii			
xxxix			
xl			
xli			
xlii			
xliii			
xliv			
xlv			
xlvi			
xlvii			
xlviii			
xlix			
1			
li			
lii			
liii			
liv			
lv			
lvi			 

lvii			
lviii			
lix			
lx			
lxi			
lxii			
lxiii			
lxiv			
lxv			
lxvi			
lxvii			
lxviii			
lxix			
lxx			
lxxi			
lxxii			
lxxiii			
lxxiv			
lxxv			
lxxvi			
lxxvii			
lxxvii			
lxxix			
lxxx			
lxxxi			
lxxxii			
lxxxii			
lxxxiv			
lxxxv			
lxxxvi			
lxxxvi			
lxxxvi			
lxxxix			
хс			
xci			
xcii			
xciii			
xciv			
xcv			
xcvi			
xcvii			
xcviii			

## Case 23-11661-KBO Doc 488 Filed 05/13/24 Page 8 of 12

#### Debtor's Name Lodo Therapeutics Corporation

ſ		xcix				
		с				
	c. All professional fees and expenses (debtor & committees)					

Pa	art 6: Postpetition Taxes	Current Month	Cumulative
a.	Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b.	Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c.	Postpetition employer payroll taxes accrued	\$0	\$0
d.	Postpetition employer payroll taxes paid	\$0	\$0
e.	Postpetition property taxes paid	\$0	\$0
f.	Postpetition other taxes accrued (local, state, and federal)	\$0	\$0
g.	Postpetition other taxes paid (local, state, and federal)	\$0	\$0
Pa	rt 7: Questionnaire - During this reporting period:		
a.	Were any payments made on prepetition debt? (if yes, see Instructions)	Yes 🔿 No 💿	
b.	Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions)	Yes 🔿 No 💿	
c.	Were any payments made to or on behalf of insiders?	Yes 🔿 No 💿	
d.	Are you current on postpetition tax return filings?	Yes 💿 No 🔿	
e.	Are you current on postpetition estimated tax payments?	Yes 💿 No 🔿	
f.	Were all trust fund taxes remitted on a current basis?	Yes 💿 No 🔿	
g.	Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions)	Yes 🔿 No 💿	
h.	Were all payments made to or on behalf of professionals approved by the court?	Yes 🔿 No 🔿 N/A 💿	
i.	Do you have: Worker's compensation insurance?	Yes 💿 No 🔿	
	If yes, are your premiums current?	Yes 💿 No 🔿 N/A 🔿	(if no, see Instructions)
	Casualty/property insurance?	Yes 💿 No 🔿	
	If yes, are your premiums current?	Yes 💿 No 🔿 N/A 🔿	(if no, see Instructions)
	General liability insurance?	Yes 💿 No 🔿	
	If yes, are your premiums current?	Yes 💿 No 🔿 N/A 🔿	(if no, see Instructions)
j.	Has a plan of reorganization been filed with the court?	Yes 💿 No 🔿	
k.	Has a disclosure statement been filed with the court?	Yes 💿 No 🔿	
1.	Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?	Yes 💿 No 🔿	

Case No. 23-11662

Pa	rt 8: Individual Chapter 11 Debtors (Only)	
a.	Gross income (receipts) from salary and wages	\$0
b.	Gross income (receipts) from self-employment	\$0
c.	Gross income from all other sources	\$0
d.	Total income in the reporting period (a+b+c)	\$0
e.	Payroll deductions	\$0
f.	Self-employment related expenses	\$0
g.	Living expenses	\$0
h.	All other expenses	\$0
i.	Total expenses in the reporting period (e+f+g+h)	\$0
j.	Difference between total income and total expenses (d-i)	\$0
k.	List the total amount of all postpetition debts that are past due	\$0
1.	Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)?	Yes 🔿 No 💽
m.	If yes, have you made all Domestic Support Obligation payments?	Yes 🔿 No 🔿 N/A 💿

#### **Privacy Act Statement**

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. § 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules\_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

# <u>I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.</u>

/s/ Yale S. Bogen

Signature of Responsible Party

Financial Advisor


Title


Yale S. Bogen

Printed Name of Responsible Party


05/13/2024

Date





Case No. 23-11662



PageF

#### Ginkgo Bioworks, Inc.

#### New Ginkgo Parent : Zymergen Consolidated : Zymergen, Inc. Income Statement Feb 2024

Financial Row Ordinary Income/Expense	Amoun
Income	
4500 - Service Fee Revenue	(\$204,166.67
Total - Income Gross Profit	(\$204,166.67 (\$204,166.67
Expense	(#204,100.07
6100 - Compensation & Benefits	
6105 - Payroll Expense	\$243,528.46
6110 - Employer Payroll Tax	\$13,189.67
6111 - Employer Payroll Tax on Stock Compensation	\$8,466.56
6115 - Employee Health Insurance 6118 - Benefits - Other	(\$41,752.77 \$260,603.06
6120 - Retirement Benefits	\$14,521.91
Total - 6100 - Compensation & Benefits	\$498,556.89
6200 - Outside Services	
6232 - Contract Research	\$34,483.61
6240 - Other Outside Services	(\$93,414.14
Total - 6200 - Outside Services	(\$58,930.53
6230 - Contract Manufacturing - CMO 6400 - Rent & Facilities & Taxes	(\$59,007.50
6401 - Rent Expense	
6410 - Rent	
6411 - Straightline Rent	\$420,288.51
Total - 6410 - Rent	\$420,288.51
6470 - Utilities	\$69,390.03
6472 - Garbage Collection	\$2,305.59
6473 - Facilities operating charges 6474 - Property taxes on real estates	\$876,541.26
04/4 - Property takes on real estates 6820 - Facilities Repairs & Maintenance & Other	\$98,153.87 (\$42,965.98
total - 6401 - Rent Expense	(\$42,905.90 \$1,423,713.28
6416 - Brokerage Fees	
6417 - Loss on Lease Termination	\$10,470.84
Total - 6416 - Brokerage Fees	\$10,470.84
6450 - Office	
6451 - Office Supplies 6452 - Dues and Subscriptions	(\$35,199.55 \$4,279.26
6452 - Dues and Subscriptions 6453 - Software & Databases	\$156.244.16
6460 - Insurance	\$150,671.38
6461 - D&O Insurance	\$9,493.70
6481 - License, Fees & Permits	\$21,872.26
6484 - Postage & Shipping	(\$6,044.59
Total - 6450 - Office	\$301,316.62
6630 - Taxes 6630 - Taxes	(\$1.00
6483 - Bank Service Charges	(\$1.00) \$3,035.00
6632 - Sales Tax	\$45,000.00
Total - 6630 - Taxes	\$48,034.00
Total - 6400 - Rent & Facilities & Taxes	\$1,783,534.74
6500 - Travel & Entertainment	
6505 - Travel	(\$1,052.59
Total - 6500 - Travel & Entertainment 6550 - Information Services	(\$1,052.59
6551 - Computer Cloud Services	\$97,666.26
6552 - Computer Peripherals	(\$637.62
6553 - Network & Internet	(\$6,045.68
6554 - Non-capitalized Hardware & Software	(\$10,751.78
Total - 6550 - Information Services	\$80,231.18
6709 - Legal Fees	
6710 - Legal - General Corporate Matter 6712 - Legal - Litigation	\$1,988,501.50 (\$2,658,478.44
6/15 - IE Skepse - Other	(\$3,115.80
6716 - Patent Prosecution	(\$2,020.20
6716 - Patent Prosecution	(\$41,813.17
_6721 - Regulatory Advice	\$147,364.00
Total - 6709 - Legal Fees	(\$569,562.11
6720 - Accounting Fees	\$307,622.53
6730 - Consulting Fees 6800 - Equipment Expense	\$1,514,314.21
6811 - Equipment Maintenance Contracts - Service	(\$4,963.21
6812 - Non-Capitalized Equipment	(\$2,595.00
Total - 6800 - Equipment Expense	(\$7,558.21
6813 - Short-term Lease Expense	(\$1,501.72
6835 - Lab Supplies	
6835 - Lab Supplies	(\$22,183.25
6836 - Chemicals Total - 6835 - Lab Supplies	\$35,745.85 \$13,562.64
for a subscription of the	\$15,562:04
6911 - Amortization Expense of Intangible	\$168,214.28
6913 - Impairment of Fixed Assets - Held for Sale	\$2,910,166.95
6916 - Impairment of Goodwill	\$10,659,550.47
6917 - Impairment of Intangible Assets	\$5,463,700.14
Total - 6900 - Non Cash Expense	\$19,201,631.84
Total - Expense	\$22,701,841.37 (\$22,905,008,04
et Ordinary Income ther Income and Expenses	(\$22,906,008.04
Other Income	
9010 - Other Income	\$228,487.66
9020 - Sublease Rent Income	\$689,211.63
9050 - Interest Income	\$3.83
9100 - Gain/Loss on Sale of Asset	\$278,920.88
Total - Other Income	\$1,196,624.00
Other Expense	
9112 - Unrealized Gain/Loss	\$250.67
9114 - Chargeback between Zymergen and Ginkgo	(\$225,733.39
	\$250.67 (\$225,733.39 (\$225,482.72 \$1,422,106.72

In re: Zymergen Inc.	
----------------------	--

Statement of Cash Receipts and Disbursements

Lead Case No. 23-11661 (KBO) Reporting Period Feb. 1 - 23, 2024

Debtor	Total Disbursements
Zymergen Inc.	\$ 2,367,089
Lodo Therapeutics Corporation	see Note 1
enEvolv, Inc.	-
Genesis Acquisition Sub, LLC	-
Total	\$ 2,367,089
	Total
Debtor	Receipts
Zymergen Inc. (see Note 1)	\$ 2,096,857
Lodo Therapeutics Corporation	-
enEvolv, Inc.	-
Genesis Acquisition Sub, LLC	-
Total	\$ 2,096,857

NOTE 1 - During the reporting period, Debtor Lodo Therapeutics Corporation ("Lodo") transferred \$1,000,000 to Debtor Zymergen, Inc. ("Zymergen") as a matter of cash management. Given that this was a transfer between debtors, consistent with the monthly operating report instructions, this transfer has not been included as a disbursement on the monthly operating form for Lodo or a receipt for Zymergen.

#### In re: Zymergen Inc.

Unaudited Balance Sheet as of February 23, 2024

#### Lead Case No. 23-11661 (KBO) Reporting Period Feb. 1 - 23, 2024

				Lodo Therapeutics				Genesis Acquistion Sub,
\$ USD	Ζ	lymergen Inc.		Corporation	6	enEvolv, Inc.		LLC
Assets:								
Current assets:								
Cash and cash equivalents	\$	46,893,909	\$	510,187	\$	32,070	\$	28,428
Pre-petition restricted cash		2,014,564		-		-		-
Accounts receivable		982,923		-		-		-
Intercompany receivables		2,713,811		-		172,444		1,582,706
Other current assets		8,301,551		-		7,929		-
Total current assets	\$	60,906,758	\$	510,187	\$	212,443	\$	1,611,134
Non-current assets:								
Fixed assets held for resale	\$	2,450,000	\$	-	\$	-	\$	-
Long-term prepaids		1,385,397		-		-		-
Operating lease right of use assets		30,537,686		-		-		-
Other Receivable		2,146,263						
Deferred lease receivable		3,560,327		-		-		-
Intellectual property, net		-		-		-		-
Investments in subsidiaries		43,388,651		-		-		-
Total non-current assets	\$	83,468,324	\$	-	\$	-	\$	-
TOTAL ASSETS	\$	144,375,082	\$	510,187	\$	212,443	\$	1,611,134
<u>Liabilities:</u> Current liabilities:								
Accounts payable	\$	8,565,710	\$	-	\$	-	\$	-
Intercompany payables		1,775,653		2,011,701		-		-
Accrued expenses		3,126,184		57,114		-		-
Operating lease liabilities, current		644,492		-		-		-
Deferred revenue, current		-		-		-		-
Other current liabilities		(505,229)		-		-		-
Total current liabilities	\$	13,606,809	\$	2,068,814	\$	-	\$	-
Non-current liabilities:								
Operating lease liabilities, non-current	\$	28,557,051		-		-		-
Other long-term liabilities		-		-		-		-
Total non-current liabilities	\$	28,557,051	\$	-	\$	-	\$	-
TOTAL LIABILITIES	\$	42,163,860	\$	2,068,814	\$	-	\$	-
Equity								
Common stock	\$	-	\$	-	\$	-	\$	-
Additional paid-in capital	Ŷ	231,749,430	Ý	25,309,303	Ŷ	10,455,785	Ŷ	7,620,170
Accumulated deficit and other comp. loss		(129,538,207)		(26,867,931)		(10,243,341)		(6,009,036)
Total Equity	\$	102,211,222	\$	(1,558,628)	\$	1	\$	<b>1,611,134</b>
TOTAL LIABILITIES AND EQUITY	Ś	144,375,082	\$	510,187	\$	212,443	\$	1,611,134

#### Note:

The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such infromation is preliminary, unaudited, and subject to change.